The treatment of early and advanced thyroid cancer is rapidly changing due to developments in targeted drug therapy and new surgical and minimally invasive approaches.  This session will familiarize the learner with the new targeted agents and their appropriate place in the treatment algorithms. 

This session will review the latest science in the field of head and neck cancer.

This session will review the latest science in the field of head and neck cancer.

This session covers the history of elective nodal irradiation and how doses were originally selected. Also covered will be how these doses changed as the field moved to IMRT. Failure rates in the elective nodal fields is examined.

There are many ongoing advances in neoadjuvant immunotherapy in curative-intent head and neck cancer, yet optimal incorporation and biomarkers remain undefined.

Virally mediated head and neck cancers caused by the Human Papilloma Virus (HPV) and the Epstein-Barr Virus (EBV) are increasing in the United States and are a global health problem.

Advanced cutaneous SCC is becoming more prevalent, with more aggressive disease noted.

This session reviews head and neck cancers from a patient perspective.

This session reviews head and neck cancers from a patient perspective.

Despite rapid advances in systemic regimens, reirradiation technology, and an expanding pipeline of therapies for recurrent/metastatic HNSCC, we need evidence-based frameworks to select appropriate candidates and plan safe re-irradiation, reassess resectability and coordinate timing of surgery af